News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
FDA OKs Widened Use of Merck & Co., Inc.'s (JOBS) Isentress HIV Drug
July 10, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Merck & Co on Thursday said U.S. regulators had widened the approved use of its Isentress HIV treatment to include patients who have not yet been treated for infections with the virus that causes AIDS.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
MORE ON THIS TOPIC
FDA
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
September 23, 2026
·
2 min read
·
Jef Akst
FDA
Compass vows to press on with FDA application despite new trial request
September 22, 2026
·
3 min read
·
Annalee Armstrong
Rare diseases
Mikhail, Davis on board with regulatory framework tailored to rare disease therapies
September 21, 2026
·
6 min read
·
Heather McKenzie
Approvals
Ultragenyx wins FDA greenlight for first Sanfilippo therapy, priced at nearly $4M
September 18, 2026
·
3 min read
·
Tristan Manalac